Literature DB >> 30244405

Application of Deacetylated Poly-N-Acetyl Glucosamine Nanoparticles for the Delivery of miR-126 for the Treatment of Cecal Ligation and Puncture-Induced Sepsis.

Joy N Jones Buie1, Yue Zhou1,2, Andrew J Goodwin3, James A Cook4, John Vournakis5, Marina Demcheva5, Ann-Marie Broome4,6, Suraj Dixit6, Perry V Halushka7,8, Hongkuan Fan9,10.   

Abstract

Sepsis is an acute inflammatory syndrome in response to infection. In some cases, excessive inflammation from sepsis results in endothelial dysfunction and subsequent increased vascular permeability leading to organ failure. We previously showed that treatment with endothelial progenitor cells, which highly express microRNA-126 (miR-126), improved survival in mice subjected to cecal ligation and puncture (CLP) sepsis. miRNAs are important regulators of gene expression and cell function, play a major role in endothelial homeostasis, and may represent an emerging therapeutic modality. However, delivery of miRNAs to cells in vitro and in vivo is challenging due to rapid degradation by ubiquitous RNases. Herein, we developed a nanoparticle delivery system separately combining deacetylated poly-N-acetyl glucosamine (DEAC-pGlcNAc) polymers with miRNA-126-3p and miRNA-126-5p and testing these combinations in vitro and in vivo. Our results demonstrate that DEAC-pGlcNAc polymers have an appropriate size and zeta potential for cellular uptake and when complexed, DEAC-pGlcNAc protects miRNA from RNase A degradation. Further, DEAC-pGlcNAc efficiently encapsulates miRNAs as evidenced by preventing their migration in an agarose gel. The DEAC-pGlcNAc-miRNA complexes were taken up by multiple cell types and the delivered miRNAs had biological effects on their targets in vitro including pERK and DLK-1. In addition, we found that delivery of DEAC-pGlcNAc alone or DEAC-pGlcNAc:miRNA-126-5p nanoparticles to septic animals significantly improved survival, preserved vascular integrity, and modulated cytokine production. These composite studies support the concept that DEAC-pGlcNAc nanoparticles are an effective platform for delivering miRNAs and that they may provide therapeutic benefit in sepsis.

Entities:  

Keywords:  Endothelial dysfunction; Inflammation; Organ dysfunction; Polymicrobial sepsis; miRNA delivery

Mesh:

Substances:

Year:  2019        PMID: 30244405      PMCID: PMC6380957          DOI: 10.1007/s10753-018-0882-8

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  7 in total

1.  Deacetylated-poly-N-acetylglucosamine-folic Acid as a Nanocarrier for Delivering miR-196a Inhibitor to Anticancer Activity.

Authors:  Yuxia Hao; Xi Li
Journal:  Balkan Med J       Date:  2022-01-25       Impact factor: 2.021

2.  Upregulating MicroRNA-410 or Downregulating Wnt-11 Increases Osteoblasts and Reduces Osteoclasts to Alleviate Osteonecrosis of the Femoral Head.

Authors:  Yukun Yin; Lixiang Ding; Yu Hou; Haoran Jiang; Ji Zhang; Zhong Dai; Genai Zhang
Journal:  Nanoscale Res Lett       Date:  2019-12-18       Impact factor: 5.418

Review 3.  The Potential of Drug Delivery Nanosystems for Sepsis Treatment.

Authors:  Yi Shi; Meng-Lu Zhu; Qian Wu; Yi Huang; Xiao-Ling Xu; Wei Chen
Journal:  J Inflamm Res       Date:  2021-12-19

4.  miR-126 ameliorates multiple organ dysfunction in septic rats by regulating the differentiation of Th17/Treg.

Authors:  Qi Zou; Cheng Liu; Nan Hu; Wei Wang; Huaxue Wang
Journal:  Mol Biol Rep       Date:  2022-02-05       Impact factor: 2.742

Review 5.  Role of miRNA dysregulation in sepsis.

Authors:  Amanda Formosa; Paul Turgeon; Claudia C Dos Santos
Journal:  Mol Med       Date:  2022-08-19       Impact factor: 6.376

Review 6.  Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes.

Authors:  Giuseppina Emanuela Grieco; Noemi Brusco; Giada Licata; Laura Nigi; Caterina Formichi; Francesco Dotta; Guido Sebastiani
Journal:  Int J Mol Sci       Date:  2019-12-17       Impact factor: 5.923

7.  MicroRNA-126 Level Increases During Exercise Rehabilitation of Heart Failure with a Preserved Ejection Fraction.

Authors:  Dong Jin; Xiu-Yun Yang; Jie-Sheng Wang
Journal:  Int J Gen Med       Date:  2021-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.